Clinical Trial Update: Single and Repeat Dose First Time in Human Study for an Intranasal H1/H3 Dual Antagonist in Healthy Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 first-in-human study of an intranasal H1/H3 dual antagonist in healthy male volunteers, evaluating single and repeat-dose administration; the study has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Seasonal Allergic Rhinitis

Drugs mentioned

• Intranasal H1/H3 dual antagonist

Snippet

Sponsor: GlaxoSmithKline | Conditions: Rhinitis, Allergic, Seasonal | Phase 1 | Status: COMPLETED